- Home
- SCHW vs BCTXW Comparison
SCHW vs BCTXW Comparison
Compare SCHW & BCTXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCHW
- BCTXW
- Stock Information
- Founded
- SCHW 1971
- BCTXW N/A
- Country
- SCHW United States
- BCTXW Canada
- Employees
- SCHW N/A
- BCTXW 12
- Industry
- SCHW Investment Bankers/Brokers/Service
- BCTXW Biotechnology: Pharmaceutical Preparations
- Sector
- SCHW Finance
- BCTXW Health Care
- Exchange
- SCHW Nasdaq
- BCTXW Nasdaq
- Market Cap
- SCHW N/A
- BCTXW N/A
- IPO Year
- SCHW 1987
- BCTXW N/A
- Fundamental
- Price
- SCHW $80.63
- BCTXW $0.28
- Analyst Decision
- SCHW Buy
- BCTXW
- Analyst Count
- SCHW 15
- BCTXW 0
- Target Price
- SCHW $75.73
- BCTXW N/A
- AVG Volume (30 Days)
- SCHW 8.0M
- BCTXW N/A
- Earning Date
- SCHW 10-15-2024
- BCTXW N/A
- Dividend Yield
- SCHW 1.24%
- BCTXW N/A
- EPS Growth
- SCHW N/A
- BCTXW N/A
- EPS
- SCHW 2.56
- BCTXW N/A
- Revenue
- SCHW $18,736,000,000.00
- BCTXW N/A
- Revenue This Year
- SCHW $4.79
- BCTXW N/A
- Revenue Next Year
- SCHW $11.05
- BCTXW N/A
- P/E Ratio
- SCHW $31.50
- BCTXW N/A
- Revenue Growth
- SCHW N/A
- BCTXW N/A
- 52 Week Low
- SCHW $55.42
- BCTXW N/A
- 52 Week High
- SCHW $82.50
- BCTXW N/A
- Technical
- Relative Strength Index (RSI)
- SCHW 78.02
- BCTXW N/A
- Support Level
- SCHW $72.90
- BCTXW N/A
- Resistance Level
- SCHW $82.50
- BCTXW N/A
- Average True Range (ATR)
- SCHW 1.60
- BCTXW 0.00
- MACD
- SCHW 0.66
- BCTXW 0.00
- Stochastic Oscillator
- SCHW 84.68
- BCTXW 0.00
About BCTXW BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.